Business & Finance

Cylex announces first quarter revenues increased 74% over Q1 2005

Published in Blood Weekly, June 1st, 2006

Cylex Incorporated, a life sciences company and leader in immune function testing, announced a 74% increase in first quarter revenues in 2006 to $603,000, up from 2005's first quarter revenues of $346,000.

Clinical revenues alone increased 84% from 2005's first quarter. In fact, clinical sales have grown 48% in the current six months compared to the previous six months.

Cylex Inc. also noted that its flagship product, ImmuKnow, the first and only FDA-cleared cellular assay for measuring and managing the health of a patient's immune system, has significantly expanded its customer base in the organ transplant market. The ImmuKnow assay is now being...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-06-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry